Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + dihydrocodeine is a combination analgesic medication used for the treatment of moderate to moderately severe pain, especially when pain is not adequately controlled by paracetamol or non-opioid analgesics alone. Paracetamol (also known as acetaminophen) acts centrally to inhibit prostaglandin synthesis, providing analgesic and antipyretic effects. Dihydrocodeine is a semi-synthetic opioid that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering both the perception of and response to pain. The combination provides greater pain relief than either agent alone due to their complementary mechanisms of action[5][6][8]. This medication is available by prescription in various strengths and formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + dihydrocodeine.